{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:34:33Z","timestamp":1762522473150,"version":"build-2065373602"},"reference-count":26,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA219603","DE028172"],"award-info":[{"award-number":["CA219603","DE028172"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GINOP","award":["GINOP_2.3.2-15-2016-00020"],"award-info":[{"award-number":["GINOP_2.3.2-15-2016-00020"]}]},{"name":"National Research, Development and Innovation Office","award":["ANN 128524","K105132","K116295"],"award-info":[{"award-number":["ANN 128524","K105132","K116295"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,5,2]]},"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The clinical response to immune checkpoint inhibitors (ICIs) in only part of the treated patients, in conjunction with the potentially serious side effects associated with this type of therapy, has emphasized the need to identify biomarkers to select patients who may benefit from ICI treatment. The aim of our study was to test human leukocyte antigen (HLA) class I and II expression in melanoma metastases as potential biomarkers of response to ipilimumab and survival in patients with metastatic melanoma, since these molecules play a crucial role in the interactions of malignant cells with host\u2019s immune system.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>HLA class I and II antigen expression level in pretreatment surgical tissue samples (50 lymph node and 35 cutaneous or subcutaneous metastases) from 30 patients was analyzed by immunohistochemical staining with monoclonal antibodies. Expression levels were correlated to intratumoral density of lymphocytes expressing cluster of differentiation (CD)8, CD45RO, CD4, forkhead box P3 (FOXP3) and\/or programmed cell death protein 1 (PD-1), to clinical response to treatment, and to patients\u2019 survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>HLA class I antigen expression level in lymph node metastases, but not in cutaneous or subcutaneous metastases was significantly correlated to density of CD8<jats:sup>+<\/jats:sup> and CD45RO<jats:sup>+<\/jats:sup> T cells and of lymphocytes expressing PD-1, as well as to clinical response and to patients\u2019 survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results corroborate the role of HLA class I expression level (alone or in combination with T-cell density values) as a predictive biomarker of response to ipilimumab in patients with melanoma. In addition, our results show that this association is influenced by the anatomic site of the metastasis used to measure the HLA class I antigen expression level.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2019-000209","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T01:54:33Z","timestamp":1592445273000},"page":"e000209","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9304-8473","authenticated-orcid":false,"given":"Andrea","family":"Lad\u00e1nyi","sequence":"first","affiliation":[{"name":"Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eszter","family":"Papp","sequence":"additional","affiliation":[{"name":"Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Mohos","sequence":"additional","affiliation":[{"name":"1st Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00edmea","family":"Balatoni","sequence":"additional","affiliation":[{"name":"Department of Oncodermatology, National Institute of Oncology, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Liszkay","sequence":"additional","affiliation":[{"name":"Department of Oncodermatology, National Institute of Oncology, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Ol\u00e1h","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Varga","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsanna","family":"Lengyel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology and Oncodermatology, University of P\u00e9cs Clinical Center, P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Emri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Debrecen Medical School and Health Science Center, Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2900-8834","authenticated-orcid":false,"given":"Soldano","family":"Ferrone","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.1","DOI":"10.1038\/nature21349"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.2","DOI":"10.1158\/1078-0432.CCR-17-2267"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.3","DOI":"10.1186\/s40425-017-0243-4"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.4","DOI":"10.1016\/j.coi.2013.02.009"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.5","DOI":"10.1016\/S0065-2776(08)60911-6"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.6","DOI":"10.1007\/s00262-018-2131-2"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.7","DOI":"10.1056\/NEJMoa1604958"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.8","DOI":"10.1158\/2159-8290.CD-17-0593"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.9","DOI":"10.1038\/s41467-017-01062-w"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.10","DOI":"10.1111\/j.1399-0039.1998.tb03082.x"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.11","DOI":"10.1038\/onc.2008.273"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.12","DOI":"10.1126\/scitranslmed.aar3342"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.13","DOI":"10.1038\/ncomms10582"},{"key":"2025100314073010000_8.1.e000209.14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00262-017-2072-1","article-title":"Tumor-Infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy","volume":"67","author":"Balatoni","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2025100314073010000_8.1.e000209.15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00007890-198207000-00004","article-title":"Heterogeneous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules","volume":"34","author":"Pellegrino","year":"1982","journal-title":"Transplantation"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.16","DOI":"10.1093\/intimm\/2.2.113"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.17","DOI":"10.1016\/0022-1759(93)90300-V"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.18","DOI":"10.1634\/theoncologist.2015-0498"},{"key":"2025100314073010000_8.1.e000209.19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00070","article-title":"Tissue-dependent tumor microenvironments and their impact on immunotherapy responses","volume":"9","author":"Oliver","year":"2018","journal-title":"Front Immunol"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.20","DOI":"10.1016\/j.cell.2017.07.025"},{"key":"2025100314073010000_8.1.e000209.21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.semcancer.2019.08.011","article-title":"Immunologic and immunogenomic aspects of tumor progression","volume":"60","author":"Lad\u00e1nyi","year":"2020","journal-title":"Semin Cancer Biol"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.22","DOI":"10.1158\/0008-5472.CAN-11-3218"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.23","DOI":"10.1158\/1078-0432.CCR-13-2690"},{"doi-asserted-by":"publisher","key":"2025100314073010000_8.1.e000209.24","DOI":"10.1158\/1078-0432.CCR-15-1507"},{"key":"2025100314073010000_8.1.e000209.25","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","article-title":"Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: a systematic review and meta-analysis","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100314073010000_8.1.e000209.26","first-page":"P48","article-title":"Different impact of immune cell infiltration and HLA class I expression in lymph node vs. cutaneous\/subcutaneous metastases as predictive markers in melanoma patients treated with ipilimumab","volume":"5","author":"Balatoni","year":"2017","journal-title":"J Immunother Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2019-000209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:07:38Z","timestamp":1759525658000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2019-000209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,6,17]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1136\/jitc-2019-000209"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2019-000209","relation":{},"ISSN":["2051-1426"],"issn-type":[{"type":"electronic","value":"2051-1426"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}